ADMINISTRATIVE CORE FACILITY

行政核心设施

基本信息

批准号：
7976002
负责人：
ROBERT ZYGMUNT ORLOWSKI
金额：
$ 6.47万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-07-01 至 2015-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7976002
关键词：
Academia Bioinformatics Budgets Cancer Center Clinic Collaborations Communication Congresses Consult Core Facility Dana-Farber Cancer Institute Data Development Diagnosis Disease Early Diagnosis Ensure Expenditure Extramural Activities Funding Gap Junctions Goals Hematologic Neoplasms Human Resources Industry Institution International Journals Manuscripts Mentors Minority Mission Monitor Multiple Myeloma Outcome Patients Peer Review Pennsylvania Plasma Cell Neoplasm Play Policies Preparation Prevention approach Prevention strategy Program Reviews Publications Regulation Reporting Reproduction spores Research Research Activity Research Personnel Resource Sharing Resources Review Committee Role Staging Tissues Translating Translational Research Translations Universities Videoconferences Videoconferencing Virginia Woman abstracting authority base bench to bedside career development clinically relevant data sharing improved lectures meetings member novel strategies outcome forecast programs success symposium

项目摘要

The M. D. Anderson Cancer Center Administrative Core Facility will serve as a nexus for this SPORE in Multiple Myeloma as the latter strives to develop novel approaches to the prevention, early detection, diagnosis, staging, and treatment of this hematologic malignancy. This Core's overall goals will be to provide coordination and oversight of SPORE activities, to facilitate internal and external collaborations as well as intramural and extramural communications, and to thereby expedite in every way possible the translational mission ofthe SPORE. Specific aims of this Core will include: 1. To assure the overall scientific quality and function of all of the SPORE components, including the five Projects, six Cores, and the Developmental Research and Career Development Programs; 2. To establish and monitor compliance of SPORE activities with all applicable local, state, national, and international regulations and requirements; 3. To oversee SPORE expenditures, and maintain and distribute budget information on a regular basis; 4. To organize and convene all necessary SPORE meetings, including those ofthe Internal and External Advisory Boards, utilizing the M. D. Anderson conference and videoconference capabilities, and provide summaries thereof to applicable personnel; 5. To assist the SPORE Developmental Research Program and Career Development Program Directors and Co-Directors in administering these vital components; 6. To support the preparation of all SPORE publications and other external communications; 7. To coordinate, obtain, and maintain Institutional commitments to the SPORE from the participating centers; 8. To encourage and facilitate intraand inter-SPORE communications, collaborations, and data and resource sharing; and 9. To promote communications and collaborations with other SPORE partners in both academia and industry. Through these activities, the Administrative Core will help both established and developmental projects clearly focus on their translational goals, and to identify and implement steps required to translate the research to and from the clinic to produce objective evidence of improving clinically relevant endpoints in multiple myeloma.

M.D. 安德森癌症中心行政核心设施将作为该 SPORE 的纽带多发性骨髓瘤作为后者努力开发新的方法来预防、早期检测、这种血液恶性肿瘤的诊断、分期和治疗。该核心的总体目标是提供协调和监督 SPORE 活动，以促进内部和外部合作以及校内和校外的交流，从而以各种可能的方式加快转化 SPORE 的使命。该核心的具体目标包括： 1. 确保整体科学质量和所有 SPORE 组件的功能，包括五个项目、六个核心和发展研究和职业发展计划； 2. 建立并监控 SPORE 活动的合规性符合所有适用的地方、州、国家和国际法规和要求； 3. 监督 SPORE支出，并定期维护和分发预算信息； 4. 组织和召开所有必要的 SPORE 会议，包括内部和外部顾问委员会的会议，利用 M.D. Anderson 会议和视频会议功能，并向适用人员； 5.协助SPORE发展研究计划和职业发展项目主管和联合主管管理这些重要组成部分； 6.支持准备工作所有 SPORE 出版物和其他外部通讯； 7. 协调、获取和维护参与中心对 SPORE 的机构承诺； 8. 鼓励和促进内部 SPORE 之间的通信、协作以及数据和资源共享； 9. 促进与学术界和工业界的其他 SPORE 合作伙伴进行沟通和合作。通过在这些活动中，行政核心将帮助已建立的项目和开发项目明确重点他们的转化目标，并确定和实施将研究转化为和来自临床，以提供改善多发性骨髓瘤临床相关终点的客观证据。